At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SVRA Savara Inc
Market Closed 04-11 16:00:00 EDT
2.92
+0.28
+10.61%
盘后2.93
+0.01+0.34%
19:43 EDT
| High2.93 | Low2.60 | Vol594.54K |
| Open2.63 | D1 Closing2.64 | Amplitude12.50% |
| Mkt Cap504.09M | Tradable Cap297.84M | Total Shares172.63M |
| T/O1.68M | T/O Rate0.58% | Tradable Shares102.00M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Savara Announces New Employment Inducement Grant
Business Wire · 04-11 20:05
BRIEF-Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences
Reuters · 04-07
Savara announces encore presentations from Molgramostim Phase 3 IMPALA-2 trial
TIPRANKS · 04-07
Savara Announces Encore Presentations From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at Two Upcoming Scientific Conferences
THOMSON REUTERS · 04-07
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Simply Wall St. · 04-03
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Evercore ISI Keeps Their Hold Rating on Savara (SVRA)
TIPRANKS · 04-01
Savara Inc - Terminates Atm Agreement With Evercore Effective April 2, 2025 - SEC Filing
THOMSON REUTERS · 03-31
Savara Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 03-28
Savara Q4 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate
Benzinga · 03-27
BRIEF-Savara Q4 Net Income USD -29.044 Million
Reuters · 03-27
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
THOMSON REUTERS · 03-27
Savara Q4 Net Income USD -29.044 Million
THOMSON REUTERS · 03-27
Savara Q4 Basic EPS USD -0.13 VS. Ibes Estimate USD -0.11
THOMSON REUTERS · 03-27
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Business Wire · 03-27
Savara Gets Up to $200 Million Loan From Hercules Capital
MT Newswires · 03-26
BRIEF-Savara Enters Into Non-Dilutive Debt Financing For Up To $200M With Hercules Capital
Reuters · 03-26
Savara Files Biologics License Application to US FDA for Molbreevi to Treat Lung Disease
MT Newswires Live · 03-26
Savara completes BLA submission to FDA for Molbreevi
TIPRANKS · 03-26
BRIEF-Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Reuters · 03-26
Savara Completes Submission of the Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (Apap)
THOMSON REUTERS · 03-26
Introduction
Company Name.
Savara Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App